Arne Kolstad

Arne Kolstad

Auto-generated profile, based on publicly available information

Arne Kolstad

Department of Oncology Oslo University Hospital Oslo Norway

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2016 in Blood
Verified
Journal Article
Open access
PDF file
AAAlexandra Albertsson-Lindblad
Alexandra Albertsson-Lindblad
AKArne Kolstad
Arne Kolstad
ALAnna Laurell
Anna Laurell
RRRiikka Räty
Riikka Räty
KGKirsten Grønbæk
Kirsten Grønbæk
MJMats Jerkeman
Mats Jerkeman
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter open-label phase I/II trial we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment to elderly MCL patients. Patients >65 years with untreated MCL, stage II-IV were eligible for inclusion. Primary endpoints were maximally tolerable dose (MTD) of LEN, and progression-free survival (PFS). Patients received six cycles q4w of L-B-R (L D1-14, B 90 mg/m2 iv D1-2 and R 375 mg/m2 iv D1) followed by single LEN (D1-21, q4w, cycles 7-13). 51 patients (median age 71 years) were enrolled 2009-2013. In phase I, the MTD of LEN was defined as 10 mg in cycles 2-6, and omitted in cycle 1. After six cycles, the complete remission rate (CRR) was 64% and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3 year overall survival was 73%. Infection was the most common non-hematological grade 3-5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in three patients; 2 PCP and 1 CMV retinitis. Second primary malignancies (SPM) were observed in eight patients (16%). LEN could safely be combined with R-B, when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs which may limit its use. http://clinicaltrials.gov: NCT00963534.

9 July 2021 in Leukemia
Verified
Journal Article
Closed access
PDF file
MDMette Dahl
Mette Dahl
SHSimon Husby
Simon Husby
CEChristian Winther Eskelund
Christian Winther Eskelund
SBSøren Besenbacher
Søren Besenbacher
SFSøren Fjelstrup
Søren Fjelstrup
KGKirsten Grønbæk
Kirsten Grønbæk

23 February 2016 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
KSKnut B. Smeland
Knut B. Smeland
CKCecilie E. Kiserud
Cecilie E. Kiserud
GLGrete F. Lauritzsen
Grete F. Lauritzsen
ABAnne K. Blystad
Anne K. Blystad
UFUnn‐Merete Fagerli
Unn‐Merete Fagerli
HHHarald Holte
Harald Holte
Summary: This national population‐based study aimed to investigate conditional survival and standardized mortality ratios (SMR) after high‐dose therapy with autologous stem‐cell transplantation (HDT‐ASCT) for non‐Hodgkin lymphoma (NHL), and to analyse cause of death, relapses and second malignancies. All patients ≥18 years treated with HDT‐ASCT for NHL in Norway between 1987 and 2008 were included (n = 578). Information from the Cause of Death Registry and Cancer Registry of Norway were linked with clinical data. The 5‐, 10‐ and 20‐year overall survival was 61% (95% confidence interval [CI] 56–64%), 52% (95%CI 48–56%) and 45% (95%CI 40–50%), respectively. The 5‐year survival conditional on having survived 2, 5 and 10 years after HDT‐ASCT was 81%, 86% and 93%. SMRs were 12·3 (95%CI 11·0–13·9), 4·9 (95%CI 4·1–5·9), 2·4 (95%CI 1·8–3·2) and 1·0 (95%CI 0·6–1·8) for the entire cohort and for patients having survived 2, 5 and 10 years after HDT‐ASCT respectively. Of the 281 deaths observed, 77% were relapse‐related. Treatment‐related mortality was 3·6%. The 10‐year cumulative incidence of second malignancies was 7·9% and standardized incidence ratio was 2·0 (95%CI 1·5–2·6). NHL patients treated with HDT‐ASCT were at increased risk of second cancer and premature death. The mortality was still elevated at 5 years, but after 10 years mortality equalled that of the general population.

28 October 2021 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
ÅLÅsa Lindberg
Åsa Lindberg
CEChristian Winther Eskelund
Christian Winther Eskelund
AAAlexandra Albertsson‐Lindblad
Alexandra Albertsson‐Lindblad
AKArne Kolstad
Arne Kolstad
ALAnna Laurell
Anna Laurell
MJMats Jerkeman
Mats Jerkeman
Mantle cell lymphoma (MCL) is a rare, often aggressive type of B‐cell lymphoma with poor survival and no cure. Cancer and cancer treatment has a negative impact on health‐related quality of life (HRQOL) both during active disease and in the long term, and improvement of HRQOL is a crucial objective of cancer therapy in older patients and no curative intent. Baseline HRQOL has in other lymphoma populations been shown to be predictive of outcome. Here, we explored HRQOL, and its association with survival, by the EORTC QLQ‐C30 questionnaire, before, during and after chemotherapy in a patient cohort with MCL, treated within the NLG‐MCL4 trial, designed to evaluate the addition of lenalidomide (LEN) to rituximab‐bendamustine (R‐B) as first‐line treatment. Fifty‐one patients were enrolled, median age was 71 years (range 62–84), 37 were men (73%). Pre‐treatment HRQOL was similar to scores from the reference population with healthy individuals. During treatment, HRQOL deteriorated, but reverted to the same level as the reference population after treatment. There was a correlation between physical function (p = 0.001) and role function (p = 0.006) at baseline and WHO performance status, but not with other clinical or genetic prognostic factors. None of the baseline factors were predictive for treatment related to HRQOL in this cohort. Pre‐treatment physical (p = 0.011) and role function (p = 0.032) were independent factors associated with overall survival, and physical function (p = 0.002) was also associated with progression free survival. These findings may possibly be used to design support during treatment and improve rehabilitation. Further investigations are needed for assessment of long‐term HRQOL.

1 February 2021 in Med
Verified
Journal Article
Closed access
EAEivind Heggernes Ask
Eivind Heggernes Ask
ATAstrid Tschan-Plessl
Astrid Tschan-Plessl
TGThea Johanne Gjerdingen
Thea Johanne Gjerdingen
MSMichelle Lu Sætersmoen
Michelle Lu Sætersmoen
HHHanna Julie Hoel
Hanna Julie Hoel
KMKarl-Johan Malmberg
Karl-Johan Malmberg

1 May 2015 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EBEgil S. Blix
Egil S. Blix
AKAnders B. Kildal
Anders B. Kildal
EBEirin Bertelsen
Eirin Bertelsen
AWAnders Waage
Anders Waage
JMJune H. Myklebust
June H. Myklebust
AHAnne Husebekk
Anne Husebekk
Multiple myeloma (MM) is considered an incurable B cell malignancy, although many patients can benefit from high-dose therapy with autologous stem cell transplantation (ASCT) as a first-line treatment. In non-Hodgkin lymphoma (NHL), ASCT is usually performed after relapse with curative intent. Disease progression is often associated with increased angiogenesis, in which endothelial progenitor cells (EPC) may have a central role. Here, we investigated the clinical impact of EPC levels in peripheral blood stem cell (PBSC) autografts for MM and NHL patients who received ASCT. EPC were identified by flow cytometry as aldehyde dehydrogenase(hi) CD34(+) vascular endothelial growth factor receptor 2(+) CD133(+) cells in both MM and NHL autografts. In MM, there was a positive correlation between EPC percentage and serum (s)-β2-microglobulin levels (r(2) = .371, P = .002). Unlike for NHL patients, MM patients with high numbers of infused EPC (EPC cells per kilogram) during ASCT had significant shorter progression-free survival (PFS) (P = .035), overall survival (P = .044) and time to next treatment (P = .009). In multivariate analysis, EPC cells per kilogram was a significant independent negative prognostic indicator of PFS (P = .03). In conclusion, the presence of high number of EPC in PBSC grafts is associated with adverse prognosis after ASCT in MM.